• Sorrento Therapeutics Inc (NASDAQ: SRNE) entered into a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology.

• Sofusa is a drug delivery platform that delivers biologic therapies through the skin and directly into the lymphatic system, potentially improving the efficacy and safety of immuno-oncology therapies.

• Targeting delivery to the lymphatics should also enable reduced dosing compared to traditional systemic infusions or subcutaneous injections.

• The first study resulting in this agreement is MC20711, a Phase 1b study of the administration of Ipilimumab Intra-Lymphatically using the Sofusa DoseConnect in Patients with Metastatic Melanoma.

• This agreement builds upon the previously announced exclusive licensing agreement where Sorrento licensed Mayo Clinic's Antibody-Drug-Nanoparticle albumin-bound Immune Complex platform technology.

• Price Action: SRNE shares are up 5.75% at $9.38 in the premarket session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.